

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 955-3P/CON	SERIAL NO. 09/780,953
	APPLICANT M. Suthanthiran, et al.	CONFIRMATION NO. 1712
	FILING DATE February 9, 2001	GROUP 1642 Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Alt	5,147,799	9/15/92	Bursuker, et al.			
Alt	5,278,145	1/11/94	Keller, et al.			
Alt	5,426,098	6/20/95	Carlino			
Alt	5,656,587	8/12/97	Sporn, et al.			

RECEIVED
JAN 15 2002
TC 1700

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Alt		B. Li, P. K. Sehajpal, A. Khanna, H. Vlassara, A. Cerami, K. H. Stenzel, and M. Suthanthiran, "Differential Regulation of Transforming Growth Factor β and Interleukin 2 Genes in Human T Cells: Demonstration by Usage of Novel Competitor DNA Constructs in the Quantitative Polymerase Chain Reaction," <i>J. Exp. Med.</i> (1991) 174: 1259-1262
Alt		Ashwani Khanna, Baogui Li, Kurt H. Stenzel, and Manikkam Suthanthiran, "Regulation of New DNA Synthesis in Mammalian Cells by Cyclosporine," <i>Transplantation</i> (1994) 57: 577-582
Alt		Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM, "Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene," <i>Cancer Res.</i> (1997) 57: 5564-5570 (Abstract Only)

145847_1

EXAMINER

DATE CONSIDERED

1/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



RECEIVED

JAN 10 2002

TECH CENTER 1600/2900

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
955-3P/CONSERIAL NO.
09/780,953INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
M. SuthanthiranCONFIRMATION NO.
1712

(Use several sheets if necessary)

FILING DATE
February 9, 2001GROUP 1692
Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
ALH	5,958,411	9/28/99	Logan et al.			
ALH	5,824,655	10/20/98	Border			
ALH	5,595,722	1/21/97	Grainger et al.			
ALH	5,583,103	12/10/96	Ruoslahti et al.			
ALH	5,262,319	11/16/93	Iwata et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ALH		1.	Hojo et al., "Cyclosporine Induces Cancer Progression by a Cell-autonomous Mechanism", <u>Nature</u> (1999), 397 (6719): 530-534. (1999), 397: 471-472.
ALH		2.	Gary J. Nabel, "A Transformed View of Cyclosporine", <u>Nature</u> (1999), 397 : 471-472.
ALH		3.	Carlos L. Arteaga et al. "Reversal of Tamoxifen Resistance of Human Breast Carcinomas <i>In Vivo</i> by Neutralizing Antibodies to Transforming Growth Factor- β ", <u>Journal of the National Cancer Institute</u> , (1999), 91 (1): 46-53.

EXAMINER Anne C. Hollman

DATE CONSIDERED


1/2/09

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

RECEIVED

TECH CENTER 1600/2900
JAN 10 2002FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
955-3P/CONSERIAL NO.
09/780,953INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
M. SuthanthiranCONFIRMATION NO.
1712

(Use several sheets if necessary)

FILING DATE
February 9, 2001GROUP 1642
Unassigned

ArH		4.	Wojtowicz-Praga et al. "Modulation of B16 Melanoma Growth and Metastasis by Anti-Transforming Growth Factor β Antibody and Interleukin-2", <u>Journal of Immunotherapy</u> (1996), 19 : 169-175.
ArH		5.	Carlos L. Arteaga et al. "Anti-Transforming Growth Factor (TGF)- β Antibodies Inhibit Breast Cancer Cell Tumorigenicity and Increase Mouse Spleen Natural Killer Cell Activity, <u>J. Clin. Invest.</u> (1993), 92 : 2569-2576.
ArH		6.	Magdalene Hoefer et al., "Anti-(transforming growth factor β) Antibodies with Predefined Specificity Inhibit Metastasis of Highly Tumorigenic Human Xenotransplants in nu/nu Mice", <u>Cancer Immunol Immunother</u> (1995), 41 : 302-308.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

144543_1.DOC

EXAMINER

Anne Holleran

DATE CONSIDERED

1/2/07

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.